Mebendazole – Vermox and cancer

Antiparasitic drugs – compariso

---

Short summary of differences and similarities

Although several antiparasitic agents are being investigated for their effect against cancer, they work in widely different ways:

Mebendazole:

• Destroys the cancer cell’s internal “skeleton” (microtubules) to stop cell division. Among the drugs mentioned here, it is the one most extensively studied in clinical trials.

Fenbendazole:

• Also destroys the cell’s “skeleton” but is additionally believed to create metabolic stress. It has a strong anecdotal history.

Niclosamide:

• Interrupts the cell’s energy supply while simultaneously blocking its growth signals.

Ivermectin:

• Creates internal stress in the cell and prevents it from pumping out chemotherapy, which can counteract resistance.

Hydroxychloroquine:

• Blocks the cell’s “recycling system” (autophagy), causing it to succumb to its own waste.

The point is that these different mechanisms allow for strategic combinations where cancer can be attacked from multiple angles simultaneously to achieve a stronger effect.

---

Antiparasitic agents compared

One of the most promising areas within complementary and experimental cancer treatment is repurposed drugs. A particularly interesting group consists of antiparasitic agents. Many of these substances have proven to possess potent anticancer properties, but it is crucial to understand that they do not all work the same way. Their attacks on cancer cells are widely different.

Below is a comparison of the most discussed substances and their unique mechanisms of action to provide a clear overview of their individual strengths and potential.

Mebendazole (Vermox)

• Main mechanism: Destruction of microtubules (the cell’s scaffolding)
• Mebendazole’s primary and most well-documented effect is a disruption of the cancer cells’ internal skeleton. The substance, which belongs to the benzimidazole family, works by binding to the protein tubulin and preventing it from assembling into microtubules. This effectively stops cell division (mitosis) and leads to cell death. Mebendazole is also the benzimidazole that has been the subject of the most formal clinical investigations, especially in connection with aggressive brain tumors (glioblastoma), where it has been tested as a supplement to standard chemotherapy.
• Characteristics: A direct, physical attack on the cell’s structure. It is the benzimidazole most extensively studied in human clinical trials.

See also links at the bottom of this article

Fenbendazole

Main mechanism: Destruction of microtubules (the cell’s scaffolding).

• Fenbendazole shares the same core mechanism as mebendazole, namely destroying the cancer cells’ microtubules and thereby stopping cell division. Its popularity, however, is driven more by preclinical studies (laboratory and animal trials) as well as strong patient reports and compelling anecdotal evidence.

Secondary mechanisms:

• In addition to the microtubule effect, research indicates that fenbendazole has a unique ability to stress the metabolism of cancer cells by blocking their sugar uptake. Certain studies also indicate that it can reactivate the tumor-suppressor gene p53.

Characteristics:

• Characterized by having a strong anecdotal history and a research focus on its ability to create metabolic stress.

See also links at the bottom of this article

Niclosamide

Niclosamide takes a completely different approach, which is primarily metabolic and signal-oriented.

Main mechanism: Metabolic collapse (energy blockade)

• Niclosamide acts as an “uncoupler” in the cancer cell’s power plants, the mitochondria. It simply short-circuits the process that produces energy (ATP), leading to an immediate and fatal loss of energy in the cell. Simultaneously, massive oxidative stress is created (via ROS production), further damaging the cell.

Secondary, but crucial mechanism: Signaling sabotage

• Beyond the energy blockade, niclosamide’s great strength is its ability to simultaneously inhibit a wide range of central signaling pathways that cancer cells depend on (Wnt, STAT3, mTOR, NF-κB). This hits not only growth but also the otherwise resilient cancer stem cells.

Characteristics:

• A dual attack that both removes the cell’s fuel and interrupts its internal communication.

See also links at the bottom of this article

Ivermectin

Ivermectin is again different from those mentioned above, working broadly on several systems related to cell stress and transport.

Main mechanism: Induction of oxidative stress and ion imbalance

• Like niclosamide, ivermectin can create high levels of oxidative stress (ROS) that are toxic to the cancer cell. It is also believed to affect ion channels in the cell membrane, disrupting the fragile electrical balance the cell maintains.

Secondary, but crucial mechanism: Inhibition of transport pumps

• One of the main causes of chemoresistance is that cancer cells develop pumps (such as P-glycoprotein) that actively push chemotherapy back out of the cell. Ivermectin has been shown to block these pumps. This means it can make resistant cancer cells sensitive to chemotherapy again, as the poison now remains inside the cell.

Characteristics:

• Creates internal stress and prevents the cancer cell from “pumping” out toxins.

See also links at the bottom of this article

Hydroxychloroquine (Plaquenil)

This drug, which is an antimalarial agent, has a very specific and unique mechanism.

Main mechanism: Blocking autophagy (the cell’s recycling station)

• Autophagy is a survival mechanism where the cell breaks down and recycles its own damaged parts to obtain energy and building blocks under pressure (e.g., during chemotherapy). Hydroxychloroquine blocks this process. The result is that the cancer cell cannot “clean up” after itself, leading to an accumulation of toxic waste inside. This makes the cell significantly more vulnerable and can push it toward cell death, especially when it is already stressed by other treatments.

Characteristics:

• Prevents the cancer cell from “eating itself” to survive pressure.

See also links at the bottom of this article

Artemisinin (and derivatives)

Main mechanism: Iron-activated cell death via free radicals

• Artemisinin, originally a Nobel Prize-winning drug for malaria, has a highly effective and specific mechanism of action. Cancer cells need large amounts of iron to divide rapidly, and they therefore have a much higher concentration of iron than normal, healthy cells. The artemisinin molecule contains a special chemical structure (an endoperoxide bridge) that reacts violently when it comes into contact with iron. This reaction creates an explosion of unstable and highly damaging molecules called free radicals (specifically Reactive Oxygen Species, ROS). This internal “bomb” of oxidative stress destroys the cancer cell’s membranes, proteins, and DNA from within, forcing it into cell death. The process has similarities to a specific type of cell death called ferroptosis (iron-dependent cell death).

Access in Denmark:

• The pure, most potent substance artesunate (a derivative) is a prescription drug in Denmark, while the plant Artemisia annua is typically sold as a dietary supplement.

Characteristics:

• Functions as a “Trojan horse” that exploits the cancer cell’s own iron dependency to create a targeted internal explosion.

See also links at the bottom of this article

Overview

Drug	Primary Mechanism of Action	Unique Characteristics
Mebendazole	Destruction of microtubules	Attacks the cell’s “skeleton.” Most studied in clinical trials.
Fenbendazole	Destruction of microtubules	Attacks the cell’s “skeleton.” Strong anecdotal history.
Niclosamide	Metabolic collapse (energy blockade)	Removes cell fuel and sabotages signaling pathways. Poor absorption.
Ivermectin	Induction of oxidative stress / Inhibition of pumps	Creates internal stress and counteracts chemoresistance.
Hydroxychloroquine	Inhibition of autophagy	Prevents the cell’s “recycling system” from working.
Artemisinin (and derivatives)	Iron-activated formation of free radicals (ROS)	Exploits high iron content in cancer cells to create oxidative stress.

Conclusion

The clear conclusion is that there is no single “antiparasitic” effect against cancer. Each substance represents a unique angle of attack that exploits different vulnerabilities in the cancer cell’s complex machinery. This diversity opens the door for intelligent combination treatments, where a tumor can be hit from several sides simultaneously. In the long run, a deeper understanding of these mechanisms can lead to more tailored treatment, where the choice of a repurposed drug is based on the specific biochemical profile of the individual tumor. The potential lies not in a single “miracle cure,” but in the strategic use of an entire arsenal of different, rediscovered “keys,” each of which can unlock a new door in the cancer cell’s defense.

As these are medications, it is naturally essential to discuss their use with your healthcare provider.

See also Metabolic strategy – block signaling pathways by cancer type – chart overviews

If you are in doubt about interaction, it can be checked here:

Drugs.com

See also Repurposed Drugs

See also No medicine – Plan B

Se også The parasite’s path to cancer

(to menu)

Links

Ivermectin:

Ivermectin, a potential anticancer drug derived from an antiparasitic agent (Science Direct, 2021)

• Relevance: This article provides a broad overview of the many proposed anti-cancer mechanisms for ivermectin. It mentions, among other things, the effect on Hippo, Akt/mTOR, and WNT signaling pathways, which supports the drug’s versatility.

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer (EMBO Molecular Medicine, 2014)

• Relevance: A very specific study confirming that ivermectin is an effective blocker of the WNT signaling pathway, which is a fundamental and often overactive signaling pathway in many cancers, including colorectal and breast cancer.

Targeting EGFR/PI3K/AKT/mTOR and Bax/Bcl-2/caspase3 pathways with ivermectin mediates its anticancer effects against urethane-induced non-small cell lung cancer in BALB/c mice (PubMed, 2025)

• Relevance: An animal study shows that the drug ivermectin has a strong anti-cancer effect on non-small cell lung cancer (NSCLC). The study concludes that ivermectin works by blocking the central growth signaling pathway (EGFR/PI3K/AKT/mTOR), leading to increased cell death and inhibited tumor growth.

Ivermectin and Cancer: Exploring the Potential Link (Williams Cancer Institute, 2023)

• Relevance: Ivermectin has potential as a cancer treatment by inhibiting tumor growth, inducing apoptosis, strengthening the immune system, and preventing angiogenesis. These mechanisms may supplement existing therapies, but further clinical research is necessary. Overall, Ivermectin opens new possibilities for the development of innovative cancer treatments.

Ivermectin, a potential anticancer drug derived from an antiparasitic drug (Science Direct, 2021)

• Relevance: Ivermectin, an antiparasitic macrolide, has shown promising potential as a cancer treatment by inhibiting tumor cell proliferation and promoting apoptosis through multiple signaling pathways. This opens possibilities for clinical use of ivermectin as an anti-neoplastic agent. Further research is needed to realize this potential in cancer treatment.

Fenbendazole:

Fenbendazole, Ivermectin and Mebendazole for Breast Cancer Success Stories – 37 Case Reports (The Medical Adviser, June 2025)

• Relevance: Several peer-reviewed articles and case studies suggest that Fenbendazole, Ivermectin, and Mebendazole may play an important role in the treatment of stage 4 breast cancer. Research shows that these substances have different anti-cancer mechanisms that can be effective against cancer cells. Specific studies include a protocol for Ivermectin, as well as investigations of Fenbendazole and Mebendazole in relation to breast cancer and metastases.

Fenbendazole Exhibits Antitumor Activity Against Cervical Cancer Through Dual Targeting of Cancer Cells and Cancer Stem Cells: Evidence from In Vitro and In Vivo Models (PubMed, 2025)

• Relevance: Fenbendazole can kill both common cancer cells and the difficult cancer stem cells in cervical cancer by disrupting the cells’ growth cycle. It stopped tumor growth in animal models without weight loss, in contrast to chemotherapy, and resulted in full survival in those treated. These results make fenbendazole a promising treatment choice against cervical cancer.

Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study (PubMed, 2024)

• Relevance: Fenbendazole can inhibit the growth and promote the death of ovarian cancer cells by disrupting the cell cycle and causing mitotic catastrophe. It was also shown to reduce tumor growth in mice, suggesting it could become a promising treatment for ovarian cancer. These results open possibilities for new therapies against this serious disease.

Mebendazole:

Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (PubMed, 2021)

• Relevance: Albendazole and mebendazole are broad-spectrum deworming medications that block microtubules and have shown promising anti-cancer effects in vitro and in vivo. They can be used against parasitic infections and potentially as cancer treatment, but long-term use can cause side effects like liver damage. Mebendazole is currently more popular in cancer trials due to albendazole’s toxicity.

Synergistic inhibition of proliferation and induction of apoptosis in oral tongue squamous cell carcinoma by mebendazole and paclitaxel via PI3K/AKT pathway mitigation (PubMed, 2025)

• Relevance: Mebendazole and paclitaxel have a synergistic effect on inhibiting proliferation and microtubular structures in oral tongue squamous cell carcinoma (OTSCC) by inhibiting the PI3K/AKT signaling pathway. The combination increases apoptosis markers and may be a promising treatment for OTSCC. Further research is needed to confirm their clinical potential.

In vitro evaluation of lipidic nanocarriers for mebendazole delivery to improve anticancer activity (PubMed, 2024)

• Relevance: Mebendazole nanostructures (MBZ-NLCs) are stable and contain a larger portion of the active substance than standard forms. They are ten times more effective against cancer cells and can prevent the movement of cancer cells in laboratory experiments. The results suggest that mebendazole nanostructures could become a good treatment for lung cancer, but more tests in the body are needed.

Plaquenil:

The imidazoline I₂ receptor agonist 2-BFI enhances cytotoxic activity of hydroxychloroquine by modulating oxidative stress, energy-related metabolism and autophagic influx in human colorectal adenocarcinoma cell lines (PubMed, 2025)

• Relevance: A new study shows that the substance 2-BFI (an imidazoline I2-receptor agonist) significantly enhances the cell-killing effect of the autophagy inhibitor hydroxychloroquine (HCQ) against colorectal cancer cells. The combination works by creating increased oxidative stress and disrupting cancer cell metabolism and survival mechanisms.

Malaria Drug Could Combat Chemotherapy-Resistant Head and Neck Cancers (UPMC, 2022)

• Relevance: This is an easy-to-understand summary of a study that shows a concrete example of how hydroxychloroquine is used to overcome chemo-resistance. It explains how the substance can “re-sensitize” cancer cells so that chemotherapy works again.

Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents (PubMed, 2017)

• Relevance: Chloroquine (CQ) and hydroxychloroquine (HCQ) have potential as anti-cancer treatment, especially in combination with standard therapies. They affect both cancer cells and the tumor microenvironment through autophagy inhibition and modulation of signaling pathways such as p53 and CXCR4-CXCL12. Further clinical studies are necessary to optimize dosing and treatment regimens.

Niclosamide:

Computer-aided drug discovery of a dual-target inhibitor for ovarian cancer: therapeutic intervention targeting CDK1/TTK signaling pathway and structural insights in the NCI-60 (PubMed, 2025)

• Relevance: This study identified 35 genes, including CDK1 and TTK, as important targets in ovarian cancer, which often develops resistance to treatment. NSC765690 (MCC22) was found to be a promising niclosamide analog with strong activity against both targets, which may help overcome chemotherapy resistance. The results show a data-driven approach to developing new therapies for ovarian cancer.

Niclosamide Treatment Suppressed Metastatic, Apoptotic, and Proliferative Characteristics of MDA-MB-231 Cancer Stem Cells (PubMed, 2025)

• Relevance: This study showed that niclosamide effectively induces apoptosis and stops the cell cycle in aggressive triple-negative breast cancer-CSCs in a 3D model. The treatment reduced metastasis- and resistance-related genes as well as EMT markers, which may improve treatment effectiveness against cancer. The results suggest that niclosamide can increase CSC sensitivity and prevent tumor recurrence.

Pharmacological advances and therapeutic applications of niclosamide in cancer and other diseases (PubMed, 2025)

• Relevance: Niclosamide is an FDA-approved drug with potential in cancer treatment, especially against resistant ovarian cancer, by modulating cell proliferation and apoptosis. New formulations and nanotechnology improve bioavailability, strengthening its therapeutic possibilities. It shows promising versatility in the treatment of cancer, viral infection, and inflammatory diseases.

Study on the mechanism of niclosamide ethanolamine salt-hydroxypropyl-β-cyclodextrin in the treatment of colon cancer based on metabolomics and 16S rRNA technology (PubMed, 2025)

• Relevance: NHC, an improved form of niclosamide, shows increased solubility and potential as a treatment for colon cancer. The analysis confirms that NHC is more effective than NES, and metabolomics as well as 16S rRNA investigate its mechanism. This may open new possibilities for niclosamide-based cancer treatment.

Antitumor activity of niclosamide-mediated oxidative stress against acute lymphoblastic leukemia (PubMed, 2024)

• Relevance: Niclosamide was shown to be able to inhibit growth and induce apoptosis in acute lymphoblastic leukemia (ALL) by increasing reactive oxygen species and activating TP53. It has potential as a new treatment to improve response and extend survival in ALL patients. These results indicate that niclosamide could become a promising therapeutic agent against ALL.

In General:

Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol (Journal of Orthomolecular Medicine)

Interactions (search for preparations) (Interaktionsdatabasen, Danish Medicines Agency)

Page created: July 1, 2024, Last revised July 2, 2025

❤

What you read on Jeg har Kræft is not a recommendation. Seek competent guidance.